PNU-282987 hydrate

• 产品号: P6499
• 分子式: C14H20Cl2N2O2
• 分子量: 319.2268
• 纯 度: ≥98% (HPLC)
• 保 存: desiccated

产品别名

• 标题: PNU-282987 hydrate
• IUPAC标准名: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide hydrate hydrochloride
• IUPAC传统名: N-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-4-chlorobenzamide hydrate hydrochloride
• 别名: N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-4-chloro-benzamide monohydrochloride hydrate

产品登记号

• PubChem SID: 24898770

产品性质

• Empirical Formula (Hill Notation): C14H17ClN2O · HCl · xH2O
• 纯度: ≥98% (HPLC)
• 外观: solid
• 溶解度: DMSO: >10 mg/mL
• 保存条件: desiccated
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (简体中文)

Caution
Air sensitive
Biochem/physiol Actions
Decreased expression of a homomeric alpha7 nicotinic acetylcholine receptor (nAChR) is connected with inability to process sensory information in schizophrenia. PNU-282987 is a novel selective agonist of the alpha7 nAChR that evoked whole-cell currents from cultured rat hippocampal neurons that were sensitive to the selective alpha7 nAChR antagonist methyllycaconitine (MLA) and enhanced GABAergic synaptic activity. The alpha7 nAChR agonist PNU-282987 improves auditory gating and enhances hippocampal oscillatory activity. These results provide further support for the concept that drugs that selectively activate alpha7 nAChRs may offer a novel, potential pharmacotherapy in treatment of schizophrenia.

详细说明 (English)

Caution
Air sensitive
Biochem/physiol Actions
Decreased expression of a homomeric alpha7 nicotinic acetylcholine receptor (nAChR) is connected with inability to process sensory information in schizophrenia. PNU-282987 is a novel selective agonist of the alpha7 nAChR that evoked whole-cell currents from cultured rat hippocampal neurons that were sensitive to the selective alpha7 nAChR antagonist methyllycaconitine (MLA) and enhanced GABAergic synaptic activity. The alpha7 nAChR agonist PNU-282987 improves auditory gating and enhances hippocampal oscillatory activity. These results provide further support for the concept that drugs that selectively activate alpha7 nAChRs may offer a novel, potential pharmacotherapy in treatment of schizophrenia.